BG
UTHR icon

Bellevue Group’s United Therapeutics UTHR Stock Holding History

Bellevue Group’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$102M Buy
188,515
+186,438
+8,976% +$105M 2.15% 13
2026
Q1 		$1.23M Sell
2,077
-1,818
-47% -$905K 0.03% 87
2025
Q4 		$1.9M Buy
3,895
+1,255
+48% +$584K 0.04% 97
2025
Q3 		$1.11M Buy
+2,640
New +$888K 0.02% 104
2023
Q1 		– Sell
-212
Closed -$59K – 173
2022
Q4 		$59K Sell
212
-89
-30% -$22.5K ﹤0.01% 163
2022
Q3 		$63K Buy
301
+108
+56% +$24.1K ﹤0.01% 165
2022
Q2 		$45K Buy
+193
New +$39.2K ﹤0.01% 167
2018
Q1 		– Sell
-17,200
Closed -$2.54M – 135
2017
Q4 		$2.54M Sell
17,200
-4,400
-20% -$559K 0.27% 72
2017
Q3 		$2.53M Buy
21,600
+13,800
+177% +$1.76M 0.26% 74
2017
Q2 		$1.01M Hold
7,800
– – 0.12% 103
2017
Q1 		$1.06M Hold
7,800
– – 0.14% 101
2016
Q4 		$1.12M Buy
7,800
+1,500
+24% +$192K 0.23% 80
2016
Q3 		$744K Hold
6,300
– – 0.13% 107
2016
Q2 		$667K Sell
6,300
-13,000
-67% -$1.45M 0.13% 107
2016
Q1 		$2.33M Buy
+19,300
New +$2.44M 0.42% 72

Other funds holding UTHR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM

Bellevue Group's UTHR Position: Q2 2026 in Review

Bellevue Group increased its United Therapeutics (UTHR) stake by 8,976% in Q2 2026, buying an estimated $105M and bringing the position to 188,515 shares worth $102M. The position accounts for 2.15% of the portfolio, ranked #13.

Bellevue Group first reported a position in UTHR in Q1 2016 and has held it in 15 quarters since. 879 funds tracked by Wall St. Rank hold UTHR as of Q2 2026.

  • Bellevue Group held 188,515 shares of United Therapeutics worth $102M as of Q2 2026.
  • Bellevue Group bought 186,438 United Therapeutics shares in Q2 2026, an estimated $105M.
  • United Therapeutics made up 2.15% of Bellevue Group's portfolio in Q2 2026, its #13 holding.
  • Bellevue Group first reported a position in United Therapeutics in Q1 2016 and has held it in 15 quarters since.
  • 879 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2026.

Based on Bellevue Group's 13F filing for Q2 2026, filed 14 Aug 2026.